Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cedaramine + azacitidine maintenance after allogeneic HSCT for high-risk AML
ChiCTR2300067593Phase 2Completed
- Sponsor
- Suzhou Hongci Hematology Hospital
- Start
- Nov 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of chidamide and azacitidine in acute myeloid leukemia (AML), sponsored by Suzhou Hongci Hematology Hospital. Primary endpoint: 2-year cumulative recurrence rate (CIR). Started Nov 2021; status: completed.
02
Drugs
chidamideazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2300067593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300067593.